Empowered Funds’s AbbVie ABBV Stock Holding History

Empowered Funds’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-19,137	Closed	-$3.09M	–	513
2022 Q4	$3.09M	Buy	+19,137	New	+$2.93M	0.2%	146

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Empowered Funds's ABBV Position: Q1 2026 in Review

Empowered Funds increased its AbbVie (ABBV) stake by 53% in Q1 2026, buying an estimated $17.4M and bringing the position to 226,836 shares worth $49.3M. The position accounts for 0.31% of the portfolio, ranked #53.

Empowered Funds first reported a position in ABBV in Q4 2017 and has held it in 22 quarters since. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Empowered Funds held 226,836 shares of AbbVie worth $49.3M as of Q1 2026.
Empowered Funds bought 78,374 AbbVie shares in Q1 2026, an estimated $17.4M.
AbbVie made up 0.31% of Empowered Funds's portfolio in Q1 2026, its #53 holding.
Empowered Funds first reported a position in AbbVie in Q4 2017 and has held it in 22 quarters since.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.